Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21298467rdf:typepubmed:Citationlld:pubmed
pubmed-article:21298467lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:21298467lifeskim:mentionsumls-concept:C0346647lld:lifeskim
pubmed-article:21298467lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:21298467lifeskim:mentionsumls-concept:C0011900lld:lifeskim
pubmed-article:21298467lifeskim:mentionsumls-concept:C0033522lld:lifeskim
pubmed-article:21298467lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:21298467lifeskim:mentionsumls-concept:C2827424lld:lifeskim
pubmed-article:21298467lifeskim:mentionsumls-concept:C2349101lld:lifeskim
pubmed-article:21298467pubmed:issue3lld:pubmed
pubmed-article:21298467pubmed:dateCreated2011-4-19lld:pubmed
pubmed-article:21298467pubmed:abstractTextThe diagnostic utility of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer (EPC) has not been properly studied, and few reports have analysed a clinically relevant spectrum of patients. The objective was to evaluate the clinical validity of detecting K-ras mutations in the diagnosis of EPC in a large sample of clinically relevant patients. We prospectively identified 374 patients in whom one of the following diagnoses was suspected at hospital admission: EPC, chronic pancreatitis, pancreatic cysts, and cancer of the extrahepatic biliary system. Mutations in the K-ras oncogene were analysed by PCR and artificial RFLP in 212 patients. The sensitivity and specificity of the K-ras mutational status for the diagnosis of EPC were 77.7% (95% CI: 69.2-84.8) and 78.0% (68.1-86.0), respectively. The diagnostic accuracy was hardly modified by sex and age. In patients with either mutated K-ras or CEA > 5 ng/ml, the sensitivity and specificity were 81.0% (72.9-87.6) and 62.6% (72.9-87.6), respectively. In patients with mutated K-ras and CEA > 5 ng/ml the sensitivity was markedly reduced. In comparisons with a variety of non-EPC patient groups sensitivity and specificity were both always greater than 75%. In this clinically relevant sample of patients the sensitivity and specificity of K-ras mutations were not sufficiently high for independent diagnostic use. However, it seems premature to rule out the utility of K-ras analysis in conjunction with other genetic and 'omics' technologies.lld:pubmed
pubmed-article:21298467pubmed:languageenglld:pubmed
pubmed-article:21298467pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21298467pubmed:citationSubsetIMlld:pubmed
pubmed-article:21298467pubmed:statusMEDLINElld:pubmed
pubmed-article:21298467pubmed:monthMarlld:pubmed
pubmed-article:21298467pubmed:issn1573-7284lld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:PortaMiquelMlld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:MalatsNúriaNlld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:CorominasJose...lld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:RifàJuliJlld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:RealFrancisco...lld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:CarratoAlfred...lld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:Hernández-Agu...lld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:FernandezEste...lld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:GuarnerLuisaLlld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:AlguacilJoanJlld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:ParkerLucy...lld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:LumbrerasBlan...lld:pubmed
pubmed-article:21298467pubmed:authorpubmed-author:LópezTomàsTlld:pubmed
pubmed-article:21298467pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21298467pubmed:volume26lld:pubmed
pubmed-article:21298467pubmed:ownerNLMlld:pubmed
pubmed-article:21298467pubmed:authorsCompleteYlld:pubmed
pubmed-article:21298467pubmed:pagination229-36lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:meshHeadingpubmed-meshheading:21298467...lld:pubmed
pubmed-article:21298467pubmed:year2011lld:pubmed
pubmed-article:21298467pubmed:articleTitleClinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients.lld:pubmed
pubmed-article:21298467pubmed:affiliationDepartment of Public Health, Miguel Hernández University, Alicante, Spain.lld:pubmed
pubmed-article:21298467pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21298467pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:21298467pubmed:publicationTypeMulticenter Studylld:pubmed
entrez-gene:3845entrezgene:pubmedpubmed-article:21298467lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21298467lld:entrezgene